CA-SYNTERACTHCR
Executives from SynteractHCR , a full-service, international contract research organization (CRO), are continuing to exhibit and speak at various industry conferences around the globe in November. The events include World Immunotherapy Congress, World Orphan Drug Congress Europe and Partnerships in Clinical Trials Europe. Each event brings together thought leaders from biotech, pharma and related industries to network and stay abreast of new developments and best practices.
The World Immunotherapy Congress , Nov. 14-16 at Congress Center in Basel, Switzerland, offers experts multiple opportunities to discuss the promising developments in immunotherapy, including immune checkpoint inhibitors and cell therapy. SynteractHCR will exhibit in booth #28 and will have clinical trial experts available to meet with companies that are focused on developing oncology and other therapeutic indication trials using immunotherapy techniques. To make an appointment to meet with SynteractHCR, contact Volker Knorz: Volker.Knorz@SynteractHCR.com .
The World Orphan Drug Congress Europe 2016 will be held Nov. 15-17 in Brussels, where Dr. Stephan de la Motte, chief medical advisor for SynteractHCR, will host two roundtables: the first on “Sharing Practical Insights on the Planning and Execution of Orphan Drug Clinical Trials ” at 11:30 am on Wed., Nov. 16th and the second on the same topic (time, date). Clients and others who might like to meet with the team at World Orphan may contact Alexandre Wallard: Alexandre.Wallard@SynteractHCR.com .
At the Partnerships in Clinical Trials Europe (PCT) event, Vice President for Global Medical and Regulatory Affairs Dr. Martine Dehlinger-Kremer will present : “Planning for the Impact of the New EU Clinical Trials Regulation and the Implications of the UK Brexit” from 11:25 a.m. – 12:00 p.m. EDT on Thursday, November 17th . Attendees will leave the presentation prepared for the upcoming EU Regulation and will better understand how Brexit may affect the new regulation. SynteractHCR will exhibit in booth #173.
Lastly, clinical trial experts from the company will also attend BVMA in Munich from Nov. 24-25th , 2016. Those who wish to meet with the team at either PCT or BVMA, or with Dr. Dehlinger-Kremer, may contact Xavier Morillon: Xavier.Morillon@SynteractHCR.com .
See SynteractHCR's full schedule of events and follow its social channels on LinkedIn and Twitter for live updates during all conferences.
About SynteractHCR
SynteractHCR is a full-service contract research organization with a successful two-decade track record supporting biotechnology, medical device and pharmaceutical companies in all phases of clinical development. SynteractHCR has conducted Phase I-IV studies on six continents and 60 countries, offering expertise across multiple therapeutic areas, with notable depth in oncology, immunotherapy, CNS, infectious disease, endocrinology, cardiovascular and respiratory, among other indications. With its “Shared Work – Shared Vision ” philosophy, SynteractHCR provides customized services collaboratively and cost effectively, ensuring on-time delivery of quality data to help bring tomorrow’s treatments to patients.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161110005548/en/
Contact:
SynteractHCR
Beth Walsh, 760-230-2424
Beth@clearpointagency.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Exstent Appoints Matt Thompson as CEO to Drive Global Growth in Personalised Aortic Support12.11.2025 08:04:00 CET | Press release
Exstent, a UK-based medical device company, developing personalised external aortic support to preserve the native aorta, today announced the appointment of Matt Thompson as Chief Executive Officer to lead its next phase of global growth. Matt brings more than two decades of combined clinical and commercial leadership to Exstent. He previously held leadership roles including President and CEO at Endologix, guiding the company through transformation, portfolio growth, and the 2021 acquisition of PQ Bypass. Earlier in his career, Matt was Professor of Vascular Surgery at St George’s Hospital, University of London, and Consultant Vascular Surgeon at St George’s Vascular Institute. His experience in integrating novel vascular technologies into established commercial frameworks aligns closely with Exstent’s strategic direction. “Exstent’s personalised external aortic support is a meaningful advance in managing ascending aortic disease,” said Matt Thompson, CEO of Exstent. “It preserves the
Ant International’s Antom Launches AI‑Powered MSME App for Finance and Business Operations12.11.2025 03:00:00 CET | Press release
The EPOS360 App integrates POS system, payments, banking, lending, and growth support into one platform to help MSMEs start, grow, and scale efficiently.The app embeds an AI copilot to simplify operations and turn business information into actionable insights.Supported by ANEXT Bank, one of the first digital banks in Singapore, MSMEs can access credit faster and manage financing with greater ease. Antom, a leading provider of merchant payment and digitisation services under Ant International, today announced EPOS360, an app that brings point-of-sale (POS) system, payments, banking, lending, and growth support together to help micro, small and medium-sized enterprises (MSMEs) move from setup to scale efficiently. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251111066634/en/ The AI-powered EPOS360 provides POS system, payments, banking, lending and other growth-enabling services, offering customised support to help MSMEs ope
Venture Global and Mitsui Announce 20-Year LNG Sales and Purchase Agreement12.11.2025 00:00:00 CET | Press release
Venture Global’s third long-term contract with a Japanese company6.75 MTPA of long-term contracts signed by Venture Global to date in 2025 Today, Venture Global, Inc. (NYSE: VG) and Mitsui & Co., Ltd. of Japan announced the execution of a new, long-term liquefied natural gas (LNG) Sales and Purchase Agreement (SPA). Under the SPA, Mitsui will purchase 1.0 million tonnes per annum (MTPA) of LNG from Venture Global for 20 years, starting in 2029. “Venture Global is honored to announce our new partnership with Mitsui, a distinguished leader in the LNG industry, to further increase the flow of U.S. LNG to Japan and the global market,” said Mike Sabel, CEO of Venture Global. “This collaboration between our two companies will strengthen energy security, enhance the balance of trade, and deepen the long-standing ties between our nations. This agreement builds upon our existing long-term relationships with Japanese companies, and we are deeply grateful for their continued trust in Venture Glob
Lattice to Showcase Advanced Industrial and Edge AI Solutions at SPS 202511.11.2025 22:00:00 CET | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced its participation in the upcoming SPS 2025, taking place on November 25 – 27, 2025 in Nuremberg, Germany. Lattice will deliver a presentation on secure motor control solutions and technology demonstrations with industry partners focused on advanced embedded vision and machine learning applications for the Industrial market. Who: Lattice Semiconductor What / When (GMT+2):Nov. 25 – 27, 2025: Embedded Vision and Machine Learning Demo Showcase EtherCAT Technology Group Booth (Hall 5, #310) Exor booth (Hall 9, #375) Nov. 25, 2025: Tech Talk (11 – 11:30 a.m.) Secure Connected Motion Control Platform for AC Motors: A Collaborative Innovation by Analog Devices and Lattice Semiconductor Where: Nuremberg Messe, Nuremberg, Germany SPS (Smart Product Solution) 2025 is one of the world’s leading trade fairs for industrial automation and digitalization. It showcases the entire spectrum of smart and digital autom
TOURISE Announces USD 113BN in Portfolio Investments to Accelerate the Future of Tourism11.11.2025 18:42:00 CET | Press release
High‑impact dealmaking at the inaugural TOURISE Summit catalyzes cross‑sector capital for growth across the global tourism ecosystem. TOURISE, the bold global platform shaping a new horizon for tourism, announced today that it has catalyzed investment portfolios totaling USD 113BN at the inaugural TOURISE Summit in Riyadh. The milestone reflects TOURISE’s mission to unlock high‑value deal flow by convening public and private sector leaders across tourism, technology, investment, and sustainability to set a shared roadmap for the next 50 years of global tourism. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251111666032/en/ His Excellency Ahmed Al Khateeb, Saudi Arabia's Minister of Tourism and Chairman of TOURISE announces USD 113 BN of investment portfolios catalyzed at the inaugural TOURISE Summit. The announced portfolio investments span the full breadth of the visitor economy: luxury retail, next‑generation hotel accomm
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom